Santhera starts Phase III trial for Friedreich’s ataxia treatment
The trial with SNT-MC17, named IONIA (idebenone effects on neurological ICARS assessments), is a double-blind, randomized, placebo-controlled study of six months duration investigating the efficacy of two doses
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.